Lee J. Harris, MD
General Neurology
Multiple Sclerosis specialist
Dr. Harris earned his medical degree from the Albert Einstein College of Medicine in New York in 1984.
After completing an internship in internal medicine, he then pursued his neurology residency at Columbia Presbyterian Medical Center, where he was Chief Resident, followed by a fellowship in clinical neurophysiology. Since completing his neurology training at Columbia, Dr. Harris has been practicing with Abington Neurological Associates since 1989. He is board certified in Neurology, with subspecialty board certifications in Clinical Neurophysiology and Electrodiagnostic Medicine.
Dr. Harris serves as Associate Director of the Abington Neurosciences Institute. He is also medical director of the Abington Balance Center and the Abington Multiple Sclerosis Center.
Abington Neurological Associates
Dr. Harris is a partner at Abington Neurological Associates, the largest private neurology practice in Montgomery and Bucks County. ANA has provided high quality comprehensive neurological care to the community for over 50 years.
The Multiple Sclerosis Center
The Multiple Sclerosis Center in Warminster is dedicated to helping Philadelphia area patients with multiple sclerosis (MS) live well by providing them with comprehensive and coordinated MS care. At the center, they organize MS treatment, rehabilitation and maintenance into a multidisciplinary program.
Dr. Weisman and His Patients Featured in Article About MCI
ANA Featured in Washington Post Article About Leqembi
Dr. Weisman Quoted in Article about Quest Rapid Alzheimer’s Test
An Open Letter to Highmark and Independence Blue Cross
FDA Converts Lecanemab to Traditional Approval
Dr. Klein Receives American Headache Society Distinguished Service Award
Dr. Weisman Quoted in Philadelphia Inquirer Article about Tofersen
FDA Gives Accelerated Approval to New ALS Treatment
Dr. Weisman participates in FDA Advisory Committee
ANA administers first lecanemab infusion in PA
Dr. Weisman Quoted in Philadelphia Inquirer Article on Lecanemab
